Over ten years ago, Arnon et al. [36] demonstrated using human prostate cancer cell lines that treatment with NKp30-Ig dramatically inhibits tumor growth in vivo in mice by successfully recruiting activated macrophages via antibody-dependent cellular cytotoxicity (ADCC). The gene discussed is NCR3; the disease is prostate carcinoma.